Biopharmaceutical company Oakrum Pharma LLC revealed on Monday the launch of an agreement to develop and manufacture two prescription generic pharmaceutical products to be commercialised in the US under the Oakrum label.
The company said it has signed the product development and commercialisation partnership with Biophore India Pharmaceuticals Pvt Ltd, a pharmaceutical company.
Both the prescription generic pharmaceutical products are expected to be sold through the specialty distribution market channel.
For the 12-month period ending 31 December 2018, the total market for the products in the US exceeded USD150m in aggregate sales, according to Bloomberg data.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets